BR0108221A - Utilização de um antagonista alpha -2b- adrenoceptor seletivo para a manufatura de um preparado farmacêutico e processo para o tratamento ou prevenção de uma enfermidade mediada pelo alfa-2b-adrenoceptor em um mamìfero - Google Patents
Utilização de um antagonista alpha -2b- adrenoceptor seletivo para a manufatura de um preparado farmacêutico e processo para o tratamento ou prevenção de uma enfermidade mediada pelo alfa-2b-adrenoceptor em um mamìferoInfo
- Publication number
- BR0108221A BR0108221A BR0108221-3A BR0108221A BR0108221A BR 0108221 A BR0108221 A BR 0108221A BR 0108221 A BR0108221 A BR 0108221A BR 0108221 A BR0108221 A BR 0108221A
- Authority
- BR
- Brazil
- Prior art keywords
- adrenoceptor
- alpha
- mammal
- antagonist
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18202100P | 2000-02-11 | 2000-02-11 | |
| FI20000303A FI20000303A0 (fi) | 2000-02-14 | 2000-02-14 | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
| PCT/FI2001/000105 WO2001058454A1 (en) | 2000-02-11 | 2001-02-07 | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0108221A true BR0108221A (pt) | 2003-03-05 |
Family
ID=26160944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0108221-3A BR0108221A (pt) | 2000-02-11 | 2001-02-07 | Utilização de um antagonista alpha -2b- adrenoceptor seletivo para a manufatura de um preparado farmacêutico e processo para o tratamento ou prevenção de uma enfermidade mediada pelo alfa-2b-adrenoceptor em um mamìfero |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1253926A1 (ru) |
| JP (1) | JP2003522148A (ru) |
| KR (1) | KR20020080413A (ru) |
| AU (1) | AU780802B2 (ru) |
| BR (1) | BR0108221A (ru) |
| CA (1) | CA2399421A1 (ru) |
| CZ (1) | CZ20022884A3 (ru) |
| EA (1) | EA200200846A1 (ru) |
| EE (1) | EE200200435A (ru) |
| GE (1) | GEP20043356B (ru) |
| HR (1) | HRP20020746A2 (ru) |
| HU (1) | HUP0300032A3 (ru) |
| IL (1) | IL151017A0 (ru) |
| IS (1) | IS6476A (ru) |
| MX (1) | MXPA02007454A (ru) |
| MY (1) | MY133957A (ru) |
| NO (1) | NO20023773D0 (ru) |
| NZ (1) | NZ520500A (ru) |
| PL (1) | PL357872A1 (ru) |
| SK (1) | SK11472002A3 (ru) |
| WO (1) | WO2001058454A1 (ru) |
| YU (1) | YU59102A (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04000615A (es) * | 2001-07-20 | 2004-04-20 | Juvantia Pharma Ltd Oy | Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. |
| FI116940B (fi) | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416432D0 (en) * | 1984-06-28 | 1984-08-01 | Wyeth John & Brother Ltd | Benzoquinolizines |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US6150389A (en) * | 1994-07-11 | 2000-11-21 | Allergan Sales, Inc. | Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents |
-
2001
- 2001-02-07 IL IL15101701A patent/IL151017A0/xx unknown
- 2001-02-07 CZ CZ20022884A patent/CZ20022884A3/cs unknown
- 2001-02-07 WO PCT/FI2001/000105 patent/WO2001058454A1/en not_active Application Discontinuation
- 2001-02-07 GE GE4893A patent/GEP20043356B/en unknown
- 2001-02-07 MX MXPA02007454A patent/MXPA02007454A/es unknown
- 2001-02-07 KR KR1020027010329A patent/KR20020080413A/ko not_active Application Discontinuation
- 2001-02-07 CA CA002399421A patent/CA2399421A1/en not_active Abandoned
- 2001-02-07 EP EP01907585A patent/EP1253926A1/en not_active Withdrawn
- 2001-02-07 AU AU35510/01A patent/AU780802B2/en not_active Ceased
- 2001-02-07 SK SK1147-2002A patent/SK11472002A3/sk unknown
- 2001-02-07 JP JP2001557564A patent/JP2003522148A/ja active Pending
- 2001-02-07 EA EA200200846A patent/EA200200846A1/ru unknown
- 2001-02-07 PL PL01357872A patent/PL357872A1/xx not_active Application Discontinuation
- 2001-02-07 YU YU59102A patent/YU59102A/sh unknown
- 2001-02-07 BR BR0108221-3A patent/BR0108221A/pt not_active IP Right Cessation
- 2001-02-07 EE EEP200200435A patent/EE200200435A/xx unknown
- 2001-02-07 HU HU0300032A patent/HUP0300032A3/hu unknown
- 2001-02-07 NZ NZ520500A patent/NZ520500A/en unknown
- 2001-02-09 MY MYPI20010579A patent/MY133957A/en unknown
-
2002
- 2002-07-19 IS IS6476A patent/IS6476A/is unknown
- 2002-08-09 NO NO20023773A patent/NO20023773D0/no not_active Application Discontinuation
- 2002-09-11 HR HRP20020746 patent/HRP20020746A2/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU780802B2 (en) | 2005-04-21 |
| EE200200435A (et) | 2003-12-15 |
| HUP0300032A2 (en) | 2003-05-28 |
| EA200200846A1 (ru) | 2002-12-26 |
| CZ20022884A3 (cs) | 2003-02-12 |
| WO2001058454A1 (en) | 2001-08-16 |
| GEP20043356B (en) | 2004-04-13 |
| EP1253926A1 (en) | 2002-11-06 |
| HRP20020746A2 (en) | 2004-12-31 |
| HUP0300032A3 (en) | 2006-01-30 |
| AU3551001A (en) | 2001-08-20 |
| KR20020080413A (ko) | 2002-10-23 |
| NZ520500A (en) | 2005-01-28 |
| MY133957A (en) | 2007-11-30 |
| JP2003522148A (ja) | 2003-07-22 |
| YU59102A (sh) | 2005-11-28 |
| CA2399421A1 (en) | 2001-08-16 |
| SK11472002A3 (sk) | 2003-02-04 |
| NO20023773L (no) | 2002-08-09 |
| IL151017A0 (en) | 2003-02-12 |
| PL357872A1 (en) | 2004-07-26 |
| NO20023773D0 (no) | 2002-08-09 |
| MXPA02007454A (es) | 2004-08-23 |
| IS6476A (is) | 2002-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0214967A (pt) | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente | |
| BR0110420A (pt) | Agonistas muscarìnicos | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| PT1326613E (pt) | Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos | |
| BR0115382A (pt) | Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica | |
| CA2375908A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| BR0108600A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória | |
| BR0313743A (pt) | Benzimidazol quinolinonas e usos destas | |
| BR0307441A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade | |
| BR0317717A (pt) | Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto | |
| EP1095656A3 (de) | Pharmazeutische Zubereitung mit dem Cholinesterase-Hemmstoff Galanthamin | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| BR0317680A (pt) | Composto, composição farmacêutica, uso de um composto, ou de um sal farmaceuticamente aceitável do mesmo, método de tratamento de um ser humano, e, processo para a preparação de um composto | |
| ATE415410T1 (de) | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| BR0308108A (pt) | Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade | |
| BR0314261A (pt) | Compostos, processo de preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de um composto, método para tratamento e/ou profilaxia de enfermidades e utilização e/ou método de tratamento | |
| ID29025A (id) | Fenilalkenoilguanidina-fenilalkenoilguanidina yang disubstitusi asam empedu, proses pembuatannya, penggunaannya sebagai obat atau diaknostik dan obat-obat yang mengandungnya | |
| WO2003000173A3 (en) | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | |
| BR0313278A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos | |
| BR0211030A (pt) | Derivado de pirrolidina oxadiazole, uso de um derivado de pirrolidina oxadiazole, composição farmacêutica contendo pelo menos um derivado de pirrolidina oxadiazole, método para preparação de um composto de pirrolidina oxadiazole | |
| BR0108221A (pt) | Utilização de um antagonista alpha -2b- adrenoceptor seletivo para a manufatura de um preparado farmacêutico e processo para o tratamento ou prevenção de uma enfermidade mediada pelo alfa-2b-adrenoceptor em um mamìfero | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| DE50006842D1 (de) | 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7O E 8O ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009 |